Results 31 to 40 of about 13,550 (188)
Антибиотики и Химиотерапия, 2021 The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj +1 more source
, 2021 Objective: To systematically review and compare the efficacy and posttreatment resistance of ceftazidime-avibactam therapy and ceftazidime-avibactam-based combination therapy in patients with Gram-negative pathogens.Methods: PubMed, Embase, Web of ...
Xiangning Huang (5216384) +6 more
core +1 more source
, 2022 This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Weiyi Shen (1835500) +3 more
core +1 more source
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae [PDF]
Clinical Microbiology and Infection, 2021 To analyse the strains collected during a 1-year survey of ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae, in order to investigate the molecular mechanisms potentially responsible for their resistant phenotype.Clinical KPC-producing K. pneumoniae isolates were collected from 31 patients in six different hospitals in Rome. For eight
Carolina, Venditti +12 more
openaire +2 more sources
Treatment of Carbapenem-Resistant Enterobacteriaceae Infections with Ceftazidime-Avibactam [PDF]
Open Forum Infectious Diseases, 2017 BACKGROUND: CRE is an urgent threats to public health with a high mortality estimated at >30–50%. Until recently, polymyxin-based antibiotics were the only available options. However, a new therapeutic option has become available: ceftazidime-avibactam. We sought to describe outcomes from these infections treated with ceftazidime-avibactam.
Rahmati, Elham +5 more
openaire +1 more source
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization [PDF]
, 2020 Objectives: The aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) strains isolated from patients with bloodstream infection.
Ambretti S. +4 more
core +1 more source
Microbiology Spectrum, 2022 As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi +8 more
doaj +1 more source
, 2023 Ceftazidime-avibactam (CZA) is one of the best therapeutic options available for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria.
Nadia Marascio (3819316) +13 more
core +1 more source
Antibiotics, 2020 Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena +19 more
doaj +1 more source
Ceftazidime/avibactam resistance is associated with different mechanisms in KPC-producing Klebsiella pneumoniae strains [PDF]
, 2021 This study focused on Klebsiella pneumoniae isolates that were resistant or had low susceptibility to a combination of ceftazidime/avibactam. We aimed to investigate the mechanisms underlying this resistance.
Cecchetto, Riccardo +9 more
core +1 more source